CBE-101 / Cell BioEngines - LARVOL DELTA

Application of DoE method to improve the rAAV Packaging Titer of Large GOIs (ASGCT 2025) - "To improve rAAV packaging titer, we employed a systematic approach using design of experiment (DoE) method to optimize transfection conditions for a therapeutic cytosine base editor (CBE101) with 4.8 kb long...These findings indicate that the use of FectoVIR®-AAV and DoE method can effectively improve transfection efficiency and rAAV packaging titer for large GOIs, providing valuable insights for future research in this area. Disease Focus of Abstract:None"

Gene Therapies

Cell BioEngines Enters Agreement with Miltenyi Bioindustry to Manufacture Hematopoietic Cell Therapy Clinical Program (GlobeNewswire) - "Cell BioEngines, Inc...today announced an agreement with Miltenyi to develop and manufacture its expanded hematopoietic stem cell transplantation (HSCT) product for clinical use in hematology-oncology...Under the terms of the agreement, Miltenyi will begin development leading towards Good Manufacturing Practices (GMP) manufacturing of the Phase 1 clinical trial batches of Cell BioEngines’ CBE-101 clinical program....Financial terms of the agreement were not disclosed."

Licensing / partnership • Hematological Malignancies • Oncology